Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited is a legitimate registered non-Hong Kong company duly registered under Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong on 1995-12-13 (operating for 30 years). According to the official register of the Hong Kong Companies Registry (CR), the entity holds an active statutory status of [Live / In Operation] (Statutory records last verified: November 2026).

The statutory primary identifiers for Grand Pharmaceutical Group Limited are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [19541746] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [F0007431] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under Part 16 of the Companies Ordinance (Cap. 622), Grand Pharmaceutical Group Limited is a Registered Non-Hong Kong Company incorporated outside Hong Kong. In Hong Kong, its registered corporate governance records comprise: 1. Latest Annual Return (Form NN3, Section 788) for current directors and company secretary; 2. Form NN7 for interim alterations of directors or secretaries; 3. Form NN8 for Authorized Representatives registered in Hong Kong (Section 786) authorized to accept legal process and notices on its behalf; and 4. Initial Application Form NN1. Because the entity was incorporated outside Hong Kong, its overall equity share capital and complete register of members are maintained under the company laws of its home jurisdiction of incorporation (and listing disclosures if publicly listed), rather than local Form NAR1 or NSC1 filings.

Yes. According to official statutory records of the Hong Kong Companies Registry, Grand Pharmaceutical Group Limited has officially recorded 3 legal name change(s): [CHINA APOLLO HOLDINGS LIMITED (effective 1995-12-13)], [MAXX Bioscience Holdings Limited (曼盛生物科技集團有限公司) (effective 2002-06-13)], [China Grand Pharmaceutical and Healthcare Holdings Limited (遠大醫藥健康控股有限公司) (effective 2008-08-04)]. Pursuant to Part 16 (Sections 778 and 779) of the Companies Ordinance (Cap. 622), where a registered non-Hong Kong company alters its corporate name in its place of incorporation, it must deliver a Return of Change of Company Name (Form NN6) to the Registrar of Companies within 1 month, and the alteration takes statutory effect in Hong Kong upon issuance of a Certificate of Registration of Alteration of Name of Registered Non-Hong Kong Company; under Hong Kong law, changing the corporate name does not affect any rights, obligations, or legal proceedings of the company.

Yes. Official filing registers of the Hong Kong Companies Registry confirm that Grand Pharmaceutical Group Limited has statutory filings on official record (latest statutory filing indexed on 2026-08-19: Form NN9 - Return of Change of Principal Place of Business in HK (Non-HK Company) (English)). Pursuant to Part 16 (Section 788) of the Companies Ordinance (Cap. 622), registered non-Hong Kong companies must deliver an Annual Return (Form NN3) to the Registrar of Companies within 42 days after each registration anniversary. Available verified original dossiers include: latest Annual Return of Non-Hong Kong Company (Form NN3 - detailing principal place of business in Hong Kong and authorised representatives), Application for Registration (Form NN1), Constitutive Documents, and Change of Secretary/Director/Authorised Representative notices (Form NN7 / NN8C), all carrying official ICRIS barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Chinese Medicine Regulatory Office (CMRO) (Licence No. CW-2009-00031); Chinese Medicine Regulatory Office (CMRO) (Licence No. PW-2008-00087); Department of Health (DH Licensed Dealer) (Licence No. 62/2A/2008); 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

The principal place of business in Hong Kong of Grand Pharmaceutical Group Limited on official record is situated at: [ROOM 02, 33/F, THE CENTRE, 99 QUEEN'S ROAD CENTRAL, CENTRAL, HONG KONG]. Official registry dossiers also record 1 statutory change of principal place of business filing(s) (Form NN9). Pursuant to Part 16 (Section 791) of the Companies Ordinance (Cap. 622), all registered non-Hong Kong companies must maintain a principal place of business in Hong Kong and notify the Registrar within 15 days of any change (Form NN9) for the lawful service of statutory notices and court process.

When executing commercial contracts or conducting cross-border due diligence on Grand Pharmaceutical Group Limited (CRN: F0007431 / 8-digit BRN: 19541746), compliance verification covers four core pillars: 1. Statutory registration & dual identifiers: verify active registration under Cap. 622 Part 16 and Inland Revenue Department Business Registration (Cap. 310); 2. Hong Kong signing authority: inspect registered directors and Hong Kong Authorized Representatives appointed under Section 786 via latest Form NN3, Form NN7, and Form NN8 (non-Hong Kong companies execute documents through registered authorized representatives or directors under their home constitution, rather than local NAR1/ND2A forms); 3. Place of incorporation verification: inspect constituent documents and public disclosures from its home jurisdiction or stock exchange; and 4. Judicial litigation screening: search High Court civil actions (HCA) and winding-up petitions (HCCW).